Patents Assigned to Tilos Therapeutics, Inc.
  • Methods of using anti-lap antibodies
    Patent number: 11230601
    Abstract: Provided herein are antibodies which bind to latency-associated peptide (LAP) of TGF-?1 and are characterized by particular functional features, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: January 25, 2022
    Assignee: Tilos Therapeutics, Inc.
    Inventors: Barbara S. Fox, Randall Burton, Stavros Kopsiaftis, Xiufeng Song, Patricia Rao, Kenneth J. Simon, Jessie M. English
  • Anti-lap antibody variants
    Patent number: 11130802
    Abstract: Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: September 28, 2021
    Assignees: Tilos Therapeutics, Inc., Merck Sharp & Dohme Corp.
    Inventors: Randall Burton, Jessie M. English, Barbara S. Fox, Stavros Kopsiaftis, Renee Moore, Patricia Rao, Kenneth J. Simon